In June 2022 the India National Anti-Doping Agency (INADA) has reported an anti-doping rule violation against the wrestler Pushpa after her sample tested positive for the prohibited substance Furosemide.
Following notification a provisional suspension was ordered. The Athlete filed a statement in her defence and she was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).
The Athlete accepted the test result and denied the intentional use of the substance. She explained with evidence that she underwent medical treatment in a hospital and that the prescribed medication Lasix had been used.
INADA contended that the Athlete had acted negligently because she had failed to mention to her doctor that she was an athlete. Further she failed to mentioned her medication on the Doping Control Form, nor made an application for a TUE.
The Panel finds that the presence of a prohibited substance had been established in the Athlete's sample and accordingly that she committed an anti-doping rule violation. In view of the evidence the Panel accepts that the violation was not intentional.
Therefore ADDPI decides on 17 October 2020 to impose a 2 year period of ineligibilty on the Athlete, starting on the date of the provisional suspension, i.e. on 7 July 2022.
